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Human pluripotent stem cells can now be routinely differentiated into cardiac cell types including
contractile cardiomyocytes, enabling the study of heart development and disease in vitro, and creating
opportunities for the development of novel therapeutic interventions for patients. Our grasp of the
system, however, remains partial, and a signiﬁcant reason for this has been our inability to effectively
purify and expand the intermediate cardiovascular progenitor cells (CPCs) equivalent to those studied in
heart development. Doing so could facilitate the construction of a cardiac lineage cell fate map, boosting
our capacity to more ﬁnely control stem cell lineage commitment to functionally distinct cardiac
identities, as well as providing a model for identifying which genes confer cardiac potential on CPCs. This
review offers a perspective on CPC development as understood from model organisms and pluripotent
stem cell systems, focusing on issues of identity as well as the signalling implicated in inducing,
expanding and patterning these cells.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Progenitor cells have conventionally been distinguished from
stem cells by their limited ability to replicate in vivo or in vitro and
their restricted differentiation capacity. Their differentiation state is
often considered more advanced, their fate being determined by
both their parent cell and the niche in which they are found. For
some tissues, like the intestine and stomach, this concept changed
with the observation that in adults, there is a progenitor cell
population that behaves like a stem cell in that it can divide
indeﬁnitely (Barker et al., 2010). Like the hematopoietic niche in
the bone marrow to produce blood, these endodermal tissues have
high turnover rates to replace cells lost daily so that an active stem
cell population is not unexpected. The heart and brain, however, are
relatively quiescent organs that were long regarded as “post-
mitotic”, with no ability to repair. This again, has turned out to be
incorrect and both organs show cell turnover and replacement after
damage, albeit at low rates (Bergmann et al., 2009; Jessberger and
Gage, 2014; Waring et al., 2014). Accordingly, neural progenitors
that can be expanded in culture have been described for adult and
foetal brain (Gage and Temple, 2013). For the heart, this has been
more contentious: cardiovascular progenitors with various identi-
ties have been observed in situ (Bearzi et al., 2007; Beltrami et al.,
2003; Laugwitz et al., 2005; Martin et al., 2004; Messina et al.,
2004; Moretti et al., 2006; Oh et al., 2003; Wu et al., 2006), and
isolated as proliferative cell cultures that should ordinarily be
restricted in differentiation to the three cardiac cell types: cardio-
myocytes, smooth muscle cells and endothelial cells. In contrast to
the various endodermal and neural progenitor populations, putative
progenitor cells from the heart have not shown stem cell features of
prolonged proliferation. If expansion of these multipotent cardio-
vascular progenitor cells (CPCs) were achieved, it would be useful in
a wide range of cardiac-related research areas, from basic develop-
mental enquiry through to cardiac disease modelling, tissue engi-
neering and cell therapy (Mercola et al., 2011; Mummery and Lee,
2013; Thavandiran et al., 2013), through either enhancing endogen-
ous CPC numbers in vivo or isolating, expanding and transplanting
cultured cells in the heart. While efforts continue towards making
practical use of primary or endogenous CPC populations in the heart
(not covered extensively here, but recently reviewed by Van Berlo
and Molkentin (2014)), increasing attention is being directed to
using self-renewing human pluripotent stem cells (PSC) for gen-
erating cardiac cells. Differentiation protocols have advanced tre-
mendously over the last few years, most particularly those based on
deﬁned media using small molecular inhibitors and growth factors
identiﬁed through developmental biology logic (Kempf et al., 2014;
Lian et al., 2013). PSC-derived cardiomyocyte-studies are burgeon-
ing, particularly in the area of cardiac disease modelling and drug
safety pharmacology (Doherty et al., 2013; Drawnel et al., 2014;
Matsa et al., 2014). Combined advances in induced pluripotent stem
cell (iPSC) and genome editing technologies now permit study of
large numbers of genetic changes on isogenic backgrounds (Li et al.,
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2014;Wang et al., 2014a; Zhang et al., 2014), where multiple disease
mutations can be introduced into a single PSC line. This also
presents an opportunity for mutation-speciﬁc drug screening and
the development of novel treatments for cardiac disease, which is
currently a major global cause of morbidity and mortality and for
which treatment options are currently inadequate (Adler et al.,
2009; Lloyd-Jones et al., 2010).
Yet in terms of developing therapies for the heart, some
fundamental challenges remain which are still restraining full
exploitation of this powerful PSC technology. These include: 1)
maintenance and expansion of PSC-derived CPCs as pure popula-
tions in a stable state, 2) efﬁcient direction of PSCs/CPCs to
ventricular, atrial and nodal cardiomyocyte subtypes, or vascular
cells and 3) maturation of these cardiomyocytes to stages beyond
those resembling the early foetal heart.
For several lineages for which the existence of progenitors with
stem cell properties has been demonstrated in primary (adult)
tissue, the isolation and maintenance of PSC-derived tissue speciﬁc
progenitors is now achievable (Cheng et al., 2012, 2013; Darabi
et al., 2012; Nakamura et al., 2014; Okabe et al., 1996; Ran et al.,
2013; Reubinoff et al., 2001; Sneddon et al., 2012), whereas less
progress has been made with CPCs. If this could be mastered in
much the same way as for PSC-derived neural progenitors, which
now serve as a stable and renewable source of multiple neural cell
types, it would signiﬁcantly enhance the options for research and
accelerate progress towards new cardiac therapeutics. One of the
principal restraints has been the uncertain molecular identity of
CPCs; during development; putative populations in the heart; and
also those derived from PSCs. This review discusses these issues
and highlights some of the existing knowledge which could guide
researchers in addressing the challenge of isolating, expanding
and differentiating PSC-derived CPCs in vitro.
Cardiovascular progenitor cells: an identity crisis?
While CPCs can easily be deﬁned functionally by their tripo-
tency in clonal analysis, their molecular identity during develop-
ment is only partially understood. The best evidence comes from
classical lineage tracing in mice, although detailed examination of
protein and gene expression during development has provided
surrogate information. These studies have shown that although
stable states may exist for certain periods of heart development,
the molecular identity of these populations (i.e. their chromatin/
epigenetic signature and gene and protein expression proﬁles)
may not be static for long, and deﬁning a spatiotemporal map of
any changes as they occur during development may be critical for
mimicking this in vitro. Conversely, deﬁning these stable or
metastable states and progression to differentiated cell types at
the clonal level using in vitro models may help us better under-
stand heart development (Fig. 1). This is particularly relevant in
studies of human heart where lineage tracing is not an option.
The earliest markers of the cardiac lineage can be seen in the
gastrulating mesoderm and include Mesp1/2 and Fgf8 (Saga et al.,
1999; Sun et al., 1999). Mesp1-driven Cre activity can be detected in
all cells of the mouse heart of mesoderm origin, and while Mesp1þ
cells contribute broadly to a number of mesodermal derivatives, a
subset appear to be dedicated cardiac progenitors (Devine et al.,
2014). These proteins are expressed transiently at this stage but have
an important role in the migration of cells to the lateral plate
mesoderm where the population takes on a crescent shape; this is
described initially as cardiogenic mesoderm as it is the site of the ﬁrst
cardiac-speciﬁc gene expression. The transcription factor Nkx2-5, the
vertebrate tinman homologue of the Drosophila fruitﬂy, is an impor-
tant early gene in this hierarchy and within the heart ﬁeld marks
deﬁnitive cardiac progenitors. Unlike tinman mutant ﬂies in which
cardiac lineage commitment is completely compromised so that the
ﬂies have no hearts, Nkx2-5 deﬁcient mice do initially form hearts,
although expression of many myocardial genes is reduced and heart
morphogenesis is abnormal (Lyons et al., 1995). This implies that
Nkx2-5 is high in the hierarchy of cardiac transcription factors.
In considering CPC populations during heart development, it is
important to be aware that an early lineage segregation takes place
into what is termed the ﬁrst heart ﬁeld (FHF), which forms the entire
left ventricle as well as other parts of the heart, and the second heart
ﬁeld (SHF), which contributes to part of the right ventricle and atria
and forms all of the outﬂow tract (see review by Buckingham et al.
(2005)). Mesp1þ cells may already be ﬁxed in their lineage fate, and
common precursors may in fact exist only prior to gastrulation
(Devine et al., 2014; Lescroart et al., 2014; Meilhac et al., 2004). The
FHF differentiates within the cardiac crescent and this ﬁeld forms the
early heart tube. The second ﬁeld, located medially to the crescent at
the point of ﬁrst differentiation, and then behind the forming heart
tube, adds onto the heart tube during its later differentiation. This SHF
encompasses the anterior heart ﬁeld marked by Fgf8/10 and is
marked more widely by the LIM homeobox transcription factor Islet
1 (Isl1) (Cai et al., 2003; Watanabe et al., 2010).
Whereas this lineage distinction is important during develop-
ment, in stem cell models that lack location-dependent diversity, the
deﬁnition of lineage may be less relevant than that of differentiation
potential. At present it is also unclear if and how precisely the
progenitors of the two heart ﬁelds are different at the molecular
level. Support for a more comparable identity comes from a study in
mice using a sensitive Cre-activated reporter based on GATA4, which
was activated by Isl1Cre and Nkx2-5Cre in very similar domains in all
four cardiac chambers (Ma et al., 2008). This suggests that differences
among CPCs, at least in terms of Isl1 and Nkx2-5 expression, may be
quantitative rather than qualitative. The transient and/or limited
expression of Isl1 in rapidly differentiating FHF progenitors may be
due to the fact that on differentiation to cardiomyocytes Nkx2-5
expression increases and may act to downregulate Isl1 as well as
other progenitor genes such as Fgf10 in the ﬁrst heart ﬁeld (Prall et
al., 2007; Watanabe et al., 2012). In Nkx2-5 null embryos, expression
of these genes can be detected in the cardiac crescent. Yet in a recent
molecular analysis of Mesp1-marked derivatives, early regional
differences have been suggested to exist (Lescroart et al., 2014).
The knowledge that Nkx2-5 and Isl1 mark multipotent CPCs
during development prompted investigations into their possible
presence in postnatal hearts. This led to the discovery of Isl1þ cells
in mouse and human neonatal heart, which when isolated from
mouse based on the Isl1-Cre/R26R directed expression of lacZ or
YFP, and cultured on cardiac mesenchyme, differentiated to cardi-
omyocytes or smooth muscle cells (Laugwitz et al., 2005; Moretti et
al., 2006). However, their number is few at birth and they are
undetectable in the adult. A variety of putative CPCs have been
identiﬁed in adult hearts based on alternative markers expressed by
stem cells in other tissues (Bearzi et al., 2007; Beltrami et al., 2003;
Martin et al., 2004; Messina et al., 2004; Oh et al., 2003). Particular
interest has focused on a population expressing the stem cell factor
(SCF) receptor c-kit, which at least at the neonatal stage encom-
passes a population with some evidence of cardiomyogenic poten-
tial (Beltrami et al., 2003; Jesty et al., 2012; Zaruba et al., 2010).
However, using a carefully validated c-kit lineage reporter mouse it
was later shown that o0.03% of cardiomyocytes derived from a
c-kit expressing population during development, and o0.01% in the
ﬁrst 6 months of postnatal life (Van Berlo et al., 2014). The
population in the heart marked by the c-kit lineage reporter instead
included 18% haematopoietic cells (CD45þ) and 77% endothelial
cells (CD31þ). So while c-kitþ cells do contribute to the developing
myocardium of the heart this new evidence suggests they may do
so extremely rarely; similarly in the adult. In vitro differentiation of
heart-derived c-kitþ cells can result in the upregulation of cardiac
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markers, but this also occurs infrequently and the derivation of
contracting cells is seldom reported. c-kit does not therefore appear
to be relevant to the CPC population observed during development
and endogenous c-kitþ lineage cells may also not be the primary
cell source for cardiomyocyte renewal in adults. The latter conclu-
sion, however, remains contentious and further replication of these
studies is probably needed to reach consensus (Nadal-Ginard et al.,
2014). More speciﬁc markers are clearly required to identify any
stem cells/progenitors in the heart with genuine myocardial differ-
entiation capacity (see review by Van Berlo and Molkentin (2014)),
and will also be important to understand how they relate to
developmental CPC populations as well as those from PSCs.
In terms of trying to deﬁne the molecular nature of CPC states, an
important question is that of when cardiac fate and therefore the
earliest CPCs are determined in vivo and therefore similarly during
PSC differentiation. Fig. 2 illustrates our simpliﬁed model for these
transitions. Although the earliest Isl1þ/Nkx2-5þ cells in the lateral
plate mesoderm clearly represent CPCs, are they merely a descendent
of a pre-determined CPC population? It is important to note that a
large part of the future SHF myocardium may be lacking Nkx2-5
expression at least at the anterior lateral plate mesoderm stage (Wu
et al., 2006), and these cells may already be pre-determined to the
cardiac lineage (Scott, 2012). Deﬁnitive earlier markers of CPCs do not
exist, but it may be critical to identify them, as once Nkx2-5 is
expressed a negative-feedback loop may compromise their self-
renewal and endothelial differentiation capacity may become
restricted or even lost (Prall et al., 2007; Wu et al., 2006).
So which other genes might deﬁne this population? As noted earlier,
Mesp1 is one of the earliest markers of the cardiac lineage, but its
expression is undetectable after gastrulation at the time when the
cardiac transcription factor Nkx2-5 becomes detectable. This has also
been seen in a recently generated dual colour MESP1mCherry/w-NKX2-
5eGFP/w hESC cardiac reporter line (Den Hartogh et al., 2014). So which
other genes might mark this intermediate population and be
required to regulate CPC development? GATA factors have been
suggested, as these are expressed early in gastrulating mesoderm
and have an important role in myocardial gene expression. Although
there is redundancy between the members, combined knockout of
GATA4 and GATA6 completely blocks myocardial development in the
mouse (Zhao et al., 2008). GATA4 is the earliest expressed family
member in the mouse cardiac lineage and may have a particularly
important role in CPCs. Although apparently unable to facilitate
cardiac gene induction when transfected alone into a gastrula-stage
embryo, when GATA4 is combined with the SWI/SNF chromatin
remodelling complex subunit Baf60c, remarkably they have this
ability (Takeuchi and Bruneau, 2009). In zebraﬁsh, overexpression
of Baf60c and GATA5 (GATA4 homologue in zebraﬁsh) promotes the
induction of a primitive CPC-like state in a cell-autonomous,
position-independent manner and these cells are capable of differ-
entiating to cardiomyocytes, endothelium and smooth muscle (Lou et
al., 2011). Mechanistically, Baf60c was shown to recruit GATA4 to
target genes to initiate CPC speciﬁcation, which is analogous to the
role of Baf complexes in MyoD recruitment in skeletal muscle (Serna
et al., 2005). Baf60c expression was shown to precede Isl1 in the
Mesp1Cre-derived lineage and occur coincidently with activation of
the Mef2cAHF, which was previously thought to be only activated
later (Devine et al., 2014). The transcription factor MEF2C may
therefore represent another important component of early CPC
identity (Lin et al., 1997). It will be important to determine how
cardiac Baf complex recruitment occurs and what the early target
genes are, and whether these cells can somehow be arrested in this
early state by regulating these signals.
Other putative CPC markers have been suggested from a study of
Nkx2-5 mutant mice and include platelet-derived growth factor
receptor alpha (Pdgfrα), insulin-like growth factor-binding protein
5 (Igfbp5), and the transmembrane protein Odz4 (Prall et al., 2007).
The VEGF receptor 2 (Flk-1/KDR) was previously shown to be co-
expressed with Pdgfrα in cardiogenic mesoderm and so may
represent another early marker (Kataoka et al., 1997). Expression
of HCN4 (hyperpolarization-activated cyclic nucleotide-gated chan-
nel 4) is also evident in cardiogenic mesoderm and the cardiac
crescent and marks cells seemingly restricted to a myocardial fate
(Garcia-Frigola et al., 2003; Liang et al., 2013; Später et al., 2013).
During human PSC differentiation, the cell-surface protein signal-
regulatory protein (SIRPA) has also been shown to be expressed in
CPCs prior to the onset of NKX2-5 expression, although its early
Multipotent CPCs
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Fig. 1. Modelling human heart development and disease using pluripotent stem cell (PSC)-derived CPCs. (a) Human heart development from CPCs within the cardiac
crescent and second heart ﬁeld. (b) Deriving, expanding and banking CPCs from PSCs and using these cells to produce differentiated cardiomyocytes or vascular cells to study
developmental processes, or (c) to apply experimental assays.
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developmental expression in vivo is unknown (Dubois et al., 2011;
Elliott et al., 2011). Whether any of these particular genes are
functionally signiﬁcant for CPCs remains to be determined.
Use of PSC models may be useful for determining how this range
of markers, some of which may be expressed in CPCs prior to NKX2-
5, reﬂect progression in the cardiac lineage and which genes are
determinants of CPC function. If pure populations of these cells
could be isolated and expanded, functional screening assays could
be envisaged to identify these genes, applying current targeted gene
deletion technology (Shalem et al., 2014; Wang et al., 2014b).
In continuing this discussion we will ﬁrst outline the signalling
events that induce the earliest cardiogenic populations in the embryo.
Lessons from embryonic heart development – signalling
important for induction, patterning, expansion and
differentiation of CPCs
Signalling regulating the induction and patterning of CPCs
During gastrulation, the future CPCs are among the ﬁrst cells to
migrate out of the primitive streak, where they were situated within
anterior mesoderm. Adjacent populations of cells, particularly endo-
derm, play an important inductive role in the cardiac lineage by
secreting instructive protein factors or morphogens, creating concen-
tration gradients that pattern progenitor populations and regulate
their differentiation. Conveniently, these early events appear to be so
well conserved between species that the same factors and pathways
identiﬁed in model organisms such as chick and zebraﬁsh are so far
proving to operate very similarly even during in vitro differentiation of
human and mouse PSC systems, which means that the details of past
and future developmental biology studies will no doubt prove indis-
pensable for further development of PSC-derived CPC methodologies.
The three families of factors with recurring roles during meso-
derm formation and cardiogenesis are the transforming growth
factor- β (TGF-β) superfamily including bone morphogenic proteins
(BMPs) and Nodal, Wnt proteins and ﬁbroblast growth factors
(FGFs). BMPs and canonical Wnts play highly conserved roles in
inducing early primitive mesoderm. Nodal is essential in mouse
embryos for positional information; it induces gastrulation but has
a graded inﬂuence with intermediate doses inducing cardiogenic
speciﬁcation. FGF signalling may act in parallel to nodal signalling as
a competence factor for mesoderm induction and it has important
roles later alongside BMP in CPC speciﬁcation (Bertocchini et al.,
2004). As suggested from many of the model systems and now
corroborated in PSC investigations, BMP, Nodal and Wnt may all
have an antagonistic effect on cardiac differentiation after gastrula-
tion or the equivalent stage in the stem cell system (Cai et al., 2013;
Naito et al., 2006; Yuasa et al., 2005). Protocols to induce cardiac
differentiation from PSCs have moved from serum-based culture
media in simple cell aggregates or inductive cell co-culture towards
deﬁned, serum-free systems, involving the sequential activation or
inhibition of the above pathways. A standard protocol involves
exposing PSCs to BMP4, Activin A (a nodal substitute) and Wnt3a
(or a GSK3 inhibitor) for 3 days followed by exposure to a Wnt
signalling inhibitor. Using such a system, MESP1þ cells appear at
day 3–4 of differentiation, PDGFRα expression increases to a peak at
around day 5–6, and NKX2-5 expression is clearly detectable by day
8, as illustrated in Fig. 3 (Elliott et al., 2011; Den Hartogh et al., 2014;
Kattman et al., 2011). The progression of differentiation from the
MESP1þ population through to the point of NKX2-5 induction is of
signiﬁcant interest as it encompasses the progressive development
of CPCs through transitional states with increasing levels of cardiac
commitment, of which the speciﬁc molecular identities remain
obscure (Fig. 2). There is increasing focus on the regulation of
chromatin remodelling induced by endoderm-derived signals. From
the Mesp1-expressing stage, it was shown that inhibition of nodal
and BMP can increase the expression of GATA4, Tbx5 and Baf60c,
which facilitates chromatin remodelling at cardiogenic loci and
primes the cell for further cardiac differentiation (Cai et al., 2013;
Lickert et al., 2004). However, we know from development that
BMP signalling, possibly in concert with FGF signalling, is important
Fig. 2. Developmental progression and differentiation of cardiovascular progenitors. Genes predicted to be expressed in multipotent or bipotent CPCs are shown, as are the
factors predicted to be involved in their self-renewal or progression/differentiation.
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for the induction of cardiac gene expression including Nkx2-5
(Alsan and Schultheiss, 2002; Keren-Politansky et al., 2009;
Liberatore et al., 2002; Lien et al., 2002; Reifers et al., 2000).
It could be that GATA4/Tbx5/Baf60c-expressing cells are optimally
poised to respond to this next wave of BMP and FGF signalling,
thereby efﬁciently upregulating Nkx2-5 and beginning the process
of more deﬁnitive cardiac differentiation.
Signalling regulating proliferation of CPCs
In the mouse embryo it has been estimated that the myocardium is
derived from a population of around 140 cardiac founder cells at
around the time of gastrulation, which contribute two-thirds/one-
third to the ﬁrst/second heart lineage (Meilhac et al., 2004). The
doubling time of these early cells has been calculated as approximately
7 h up to E8.5, and later in early myocardial cells up to E10.5 as
approximately 15 h (Meilhac et al., 2003). Therefore proliferation at
both the progenitor stage and after differentiation to cardiomyocytes is
central to heart development. The primary pathways driving prolif-
eration of CPCs are thought to be: FGF, canonical Wnt, IGF-PI3K and
sonic hedgehog (SHH). As SHF progenitors exist in a dividing,
undifferentiated state for longer, this population has been the focus
of studies on proliferation.
FGF signalling exerts a pro-proliferative effect mostly by dose-
dependently inducing ERK phosphorylation, but signalling via
PI3K/Akt can also enable proliferation. Fgf8 is produced within
the SHF but also by endoderm and ectoderm of the pharyngeal
arches. In mice, conditional or hypomorphic Fgf8 mutants must be
used to ensure gastrulation, and these mutants show that Fgf8
signalling is critical for the proliferation of the anterior SHF (Ilagan
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Fig. 3. Cardiovascular progenitor cell development and differentiation to cardiomyocytes during human pluripotent stem cell differentiation. A time-course of cardiac
differentiation using a protocol based on deﬁned factors, highlighting the expression kinetics of known markers of cardiac progenitors. Images show a representative
embryoid body from NKX2-5eGFP/w hESC reporter cells, imaged on day 4 and again on day 10 of differentiation, at which time the EB would be beating and rich in
cardiomyocytes. CHIR99021¼GSK3-inhibitor; XAV939¼Wnt pathway inhibitor.
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et al., 2006; Macatee et al., 2003; Park et al., 2006). Fgf10 is also
expressed in the SHF, and while Fgf10 mutants seem to have a
defect of cardiac morphogenesis rather than in the SHF, hetero-
zygous loss of Fgf10 exacerbates a cardiac-speciﬁc Fgf8 mutant and
leads to severely disturbed anterior heart development (Marguerie
et al., 2006; Watanabe et al., 2010). These results suggest that FGF
dosage is critical for anterior SHF proliferation and deployment.
Wnt/β-catenin signalling can induce proliferation through the
regulation of cell-cycle controlling target genes, including upregula-
tion of c-Myc, Cyclin D and c-jun, and downregulation of p21 (Vlad
et al., 2008). Wnt signalling may also stimulate FGF production and
signalling within CPCs, where Fgf10 was shown to be a direct target
(Cohen et al., 2007). While negatively modulating cardiac speciﬁca-
tion from mesoderm, numerous reports suggest a pro-proliferative
effect of canonical Wnt signalling on established CPCs (Cohen et al.,
2007; Klaus et al., 2007; Qyang et al., 2007). However, overactivation
of Wnt/β-catenin signalling can lead to a loss of SHF CPCs, and non-
canonical Wnt ligands Wnt5a and Wnt11 are required to inhibit
Wnt/β-catenin signalling and maintain this population (Cohen et al.,
2012). As well as inhibiting Isl1 expression, in some models Wnt/β-
catenin signalling was shown to lead to a downregulation in GATA
gene expression and other genes involved in cardiac development
(Afouda et al., 2008; Kwon et al., 2009; Martin et al., 2010; Novikov
and Evans, 2013; Palpant et al., 2013). So it seems that while some
Wnt/β-catenin signalling is necessary for CPC proliferation, the
signalling must be tempered to prevent loss of CPC identity.
Evidence suggesting a role for IGF signalling in CPCs is less direct
but can be inferred from a number of studies. IGF signalling is involved
in general embryonic growth, with surviving Igf-1 null mice becoming
30% of normal weight as adults (Baker et al., 1993). More speciﬁcally
for the heart, Nkx2-5Cre/Igf1r/Insr conditional null embryos have a
signiﬁcant defect in myocardial proliferation (Li et al., 2011), while
cardiac speciﬁc overexpression of nuclear Akt enhances CPC prolifera-
tion (Gude et al., 2006). PI3K and Akt are also essential for hedgehog
signalling (Madhala-Levy et al., 2012; Riobó et al., 2006), which is
another signalling pathway implicated in CPC proliferation as well as
the maintenance of many stem cell/progenitor populations (Beachy et
al., 2004). SHH is produced by the endoderm and its signalling activity
was observed in the posterior SHF of mice and has been shown to be
necessary for SHF proliferation in chick (Hoffmann et al., 2009).
Increasing hedgehog signalling was also shown to stimulate prolifera-
tion in SHF explants (Dyer et al., 2010).
Cardiomyocyte subtype speciﬁcation through CPC patterning
The mature four-chambered heart consists of cardiomyocytes
that can be classiﬁed broadly as “working” myocardium (atrial and
ventricular) and the conduction system population. Working
myocardium is characterized by its low automaticity and efﬁcient
contractile function whereas the conduction system is character-
ized by the opposite.
In terms of working myocardium, the FHF contributes both atrial
and ventricular myocytes, although atrial markers are not detectable
in the cardiac crescent of the mouse and are only distinguishable later,
where as ventricular markers such as Mlc2v are already present in
ventricular myocytes at this stage. The SHF also contributes to both
populations and is clearly patterned along its anteroposterior axis with
anterior progenitors (Isl1þ/FGF10þ) contributing to right ventricular
myocardium and posterior progenitors (Isl1þ/FGF10) contributing
solely to the atria (Galli et al., 2008). An important signalling factor
deﬁning cardiac anteroposterior patterning is retinoic acid, which
inhibits Fgf8 and Nkx2-5 gene expression in the cardiac progenitor
ﬁeld and is also important for the induction of atrial speciﬁc genes
(Drysdale et al., 1997; Sirbu et al., 2008). It was demonstrated that
retinoic acid can also promote differentiation of human embryonic
stem cells (hESCs) towards an atrial fate (Zhang et al., 2011). BMP may
also inﬂuence chamber assignment in development, with higher levels
favouring atrial over ventricular fate (Marques and Yelon, 2009).
However, little else is known in terms of atrial versus ventricular
signalling determinants.
The conduction system consists of the sinoatrial node (SAN), the
atrioventricular (AV) node, bundle of His and Purkinje ﬁbres. Much
research has focused on the origin and molecular identity of the
SAN, the pacemaker of the heart, because its dysfunction is a
common cardiac disorder. The SAN has a molecular signature
distinct from the surrounding atrial myocardium, including main-
tained expression of the hyperpolarization activated pacemaker
channel HCN4, which is important for pacemaker activity, and low
levels of Cx40 and Cx43 gap junction proteins to ensure slower
propagation rates of current than the working myocardium
(Christoffels et al., 2010). Another key molecular feature of the
primordial SAN is the early absence of Nkx2-5 expression. The
population develops from Isl1þ SHF progenitor cells which have
never expressed Nkx2-5 but which have mostly expressed Tbx18, a
gene which is ﬁrst detected caudal/lateral to the cardiac crescent
(Mommersteeg et al., 2007; Wiese et al., 2009). This absence of the
Nkx2-5-driven working myocardial programme may be a key
requirement for SAN development. Therefore in terms of SAN
speciﬁcation signalling, protection from Nkx2-5-inducing factors
(such as FGF and BMP) may be important, or else early signalling
events might render them subsequently resistant to these Nkx2-5-
inducing signals. By contrast, the AV node expresses relatively high
levels of Nkx2-5. Considerable efforts are being directed at trying to
differentiate PSCs to pacemaker cells, for disease modelling pur-
poses and also with the intention of making biological pacemakers
in the future. Promising results have been shown through genetic
means by overexpressing transcription factors important in SAN
development, namely Tbx3 and Shox2 during mouse ESC differ-
entiation (Ionta et al., (2015); Jung et al., 2014). In hESCs, inhibition
of neuregulin (NRG)-1β/ErbB signalling was shown to promote the
differentiation of nodal-type cells and inhibit induction of working-
type cardiomyocytes (Zhu et al., 2010).
Clearly more needs to be learnt about the signalling and genetic
determinants of lineage speciﬁcation from PSCs towards either work-
ing myocardium or pacemaker cells to help facilitate the efﬁcient
generation of these functionally distinct populations.
Signalling regulating differentiation of CPCs
The CPCs of the FHF and SHF will ultimately differentiate to make
up the vast majority of the heart's cardiomyocytes, and additionally
make contributions to the heart's vasculature, and perhaps also to
the endocardial inner lining of the heart. The cardiac neural crest and
the proepicardium are the other important contributors to the heart's
vascular and interstitial cells. So after the proliferative expansion of
CPCs and their appropriate patterning, a new conﬁguration of
signalling must lead to their terminal differentiation, which could
be into cardiomyocytes, smooth muscle or endothelial cells depend-
ing on the progenitor's identity and location.
Cell cycle exit may not necessarily be coupled to differentiation,
as even myocytes continue proliferating in the early (or neonatal)
heart (Porrello et al., 2011), but a reduction in proliferative signals
may be a key differentiation-inducing event, with a changing
balance of FGF and BMP signalling possibly at the crux of this
determination for the myocardial fate. As the SHF CPCs approach
the primary heart tube they are exposed to increasing BMP and
non-canonical Wnt signals and these are thought to be primary
drivers of myocardial differentiation.
In the mouse, Fgf10 expression becomes downregulated in
myocardium in response to increasing Nkx2-5-mediated repression
and loss of Isl-1-mediated activation, and this is permissive for
myocardial differentiation (Watanabe et al., 2012). Likewise, in the
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absence of epicardial- and endocardial-derived FGF signals, differ-
entiation to cardiomyocytes occurs prematurely (Lavine et al., 2005).
BMP has been shown to be continually required during myocardial
differentiation and it is actively repressed in differentiating cardio-
myocytes (Pater et al., 2012). Wnt/β-catenin may also have a
considerable fate determining inﬂuence, as its activity has been
shown to promote an endothelial over a myocardial fate (Noack
et al., 2012; Novikov and Evans, 2013; Palpant et al., 2013). By
contrast, non-canonical Wnt signalling may have a positive role on
cardiomyocyte differentiation, with Wnt11 having been shown to be
important for normal myocardialization and outﬂow-tract morpho-
genesis via an upregulation in TGF-β2 expression (Zhou et al., 2007).
In support of this, TGF-β markedly improves the cardiomyocyte
differentiation of human heart-derived progenitors (Goumans et al.,
2008). However, data suggest that this may be a late effect as earlier
exposure inhibits myocardial commitment (Willems et al., 2012), and
its inducing effect may relate at least partially to its anti-proliferative
role. New data suggest that increased mitochondrial reactive oxygen
species (ROS) may be a key mediator of cardiomyocyte cell cycle
arrest (Puente et al., 2014); ROS were also previously shown to be
elevated early in hESC-derived cardiomyocytes (Birket et al., 2013),
and as TGF-β is known to increase mitochondrial ROS, which is also
important for its gene regulatory effects, there could be a mechanistic
connection involving mitochondria (Jain et al., 2013). Finally, roles for
both SHH and IGF in cardiomyocyte commitment have been sug-
gested by some models and also merit further exploration (D’Amario
et al., 2011; Goddeeris et al., 2007; Thomas et al., 2008).
The signalling mechanisms more speciﬁcally guiding the differ-
entiation of putative multipotent CPCs to vascular cells have been less
studied, but may also be diverse. VEGF is known to be a critical factor
for the differentiation and propagation of endothelial cells and has
been used to facilitate endothelial cell differentiation from Isl1þ CPCs
of embryonic or ESC origin (Moretti et al., 2006). TGF-β, PDGF and
retinoic acid signalling pathways have been implicated in the
differentiation and proliferation of smooth muscle cells from a variety
of progenitor sources but their action on CPCs has yet to be explored
(Sinha et al., 2014). In explanted chick arterial pole progenitors, it was
shown that FGF signalling promotes proliferation and later smooth
muscle differentiation, where as BMP signalling promotes myocardial
differentiation (Hutson et al., 2010). Likewise, inhibiting BMP signal-
ling in zebraﬁsh anterior heart ﬁeld progenitors favours smooth
muscle over myocardial differentiation (Hami et al., 2011).
Pluripotent stem cell-derived cardiac progenitor cells
PSCs offer a unique opportunity to recreate the process of cardiac
development in vitro, to follow the development and progression of
CPCs, and to study the competence of clonal populations in a controlled
environment. The system is a valuable platform for testing hypotheses
that have emanated from research onmodel organisms, and presents a
rare opportunity to work in a human cell context. In this section we
will review the studies that have attempted to isolate, expand, and
differentiate PSC-derived CPCs. These have mostly focussed on the
markers: VEGFR2, Isl1 or Nkx2-5, identiﬁed using surface staining
(VEGFR2), or through the use of genetic reporter lines (Isl1 and Nkx2-
5). A common feature of these studies is the limited evidence of
expandability and so focus has mostly been on the differentiation
capacity of these cells in terms of deﬁning uni- bi- or tripotency.
The cardiac lineage arises from VEGFR2þ (Flk1/KDR) mesodermal
progenitors during development in mouse, and a number of studies
have suggested that this protein marks the same population during
ESC differentiation (Kattman et al., 2006; Motoike et al., 2003; Yang
et al., 2008). Yang et al. (2008) demonstrated that during cardiac
differentiation of hESCs, low KDR expression at around day 6 could
mark a tripotent clonal CPC population. It was later shown that this
ESC-derived population also expresses PDGFRα, equivalent to the
in vivo situation (Kataoka et al., 1997; Kattman et al., 2011). However,
in hESCs, den Hartogh et al. did not ﬁnd enrichment of KDR expression
in cardiac progenitors derived from MESP1þ cells, which were
enriched for PDGFRα, raising some doubt about the human VEGFR2
being a CPC marker in vitro (Den Hartogh et al., 2014). The surface
makers ROR2, CD13 and SIRPA may also overlap with early PSC-
derived CPCs at different stages, with SIRPA also being a useful marker
of early cardiomyocytes derived from human PSCs (Ardehali et al.,
2013; Dubois et al., 2011; Skelton et al., 2014). The cardiac progenitor
marker Isl1 becomes enriched within this PDGFRαþ population and
these putative CPCs could be isolated from Isl1-nLacZ knockin ESCs
(Moretti et al., 2006). These cells showed some capacity to expand as
colonies on cardiac mesenchyme, but still differentiated sponta-
neously, with colonies showing indications at the gene expression
level of differentiation to cardiomyocytes, smooth muscle cells and
endothelial cells. Likewise, in a human model, using transgenic ISL1-
cre DsRed hES cells, DsRedþ cells were enriched for NKX2-5 expression
and were capable of forming all 3 lineages, albeit with low efﬁciency
(4% CMs, 3% ECs, 44% SMCs) (Bu et al., 2009). The non-cardiac marker
c-kit was shown to mark a proportion of early Nkx2-5þ cells
differentiating from mESCs and to be associated with clonogenicity
(Wu et al., 2006), where as in the human system the CPC population is
c-kit at day 6 of differentiationwhich is more consistent with lineage
tracing data (Van Berlo et al., 2014; Yang et al., 2008).
Studies using these PSC systems suggest that a developmental
loss of tripotency (loss of endothelial capacity) may be concomitant
with, or occur around the time of NKX2-5 upregulation. For
example, in the Nkx2-5þ population of mESC reporter lines only
bipotency to cardiomyocytes and smooth muscle could be achieved
(Moretti et al., 2006; Wu et al., 2006), although in one NKX2-5eGFP/w
hESC reporter line early NKX2-5þ cells could also give rise to rare
endothelial cells; although tripotent differentiation from single cells
could not be demonstrated (Elliott et al., 2011). The onset of HCN4
expression may also occur concomitantly with progression to a
more restricted myocardial progenitor (Liang et al., 2013; Später et
al., 2013). Together these studies suggest that with the onset of
NKX2-5 and/or HCN4 expression, CPCs may quickly lose endothelial
differentiation capacity. It remains unclear how important VEGFR2
expression is in this regard, as endothelial cells could also be
derived from KDR cells marked by ISL1 (Bu et al., 2009). The
overlapping expression of other VEGFR family members might
explain some of this heterogeneity (Nsair et al., 2012). Interestingly,
in two colour Isl1 and Nkx2-5 reporter mESCs, cardiomyocytes could
also be produced from Nkx2-5 cells, albeit at low efﬁciency
(o20%), but there was no mention of whether they remained
Nkx2-5 similar to cells of the SAN (Domian et al., 2009;
Gittenberger‐De Groot et al., 2007; Mommersteeg et al., 2007).
A striking feature of all these studies is the limited proliferation
shown by these CPC populations. Of the 11 publications summarized
in Table 1, proliferation has only been shown over one or two passages
and in no case has stability been shown across multiple markers to
conﬁrm that the cells remain unchanged even for this period. This
raises the question of whether the requisite growth conditions have
simply not been met, or whether the cells at this stage are in a
transitional (quasi-stable) state by nature and are actually not amen-
able to stable expansion but are instead irredeemably ﬁxed on the
path of further differentiation.
Strategies to improve the utility of PSC-derived CPCs
Due to the challenges of isolating and expanding PSC-derived
CPCs, the standard approach for generating cardiomyocytes from
PSCs remains directed differentiation of one state to the other
without the isolation of an intermediate cell population. While this
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strategy has served researchers well and allowed differentiation
protocols to be improved and better understood, the approach can
be variable in its efﬁciency due to the demanding number of
specifying steps which must be made each time. Line-to-line
variability can also be problematic. The option to work with
lineage-restricted progenitors would have many advantages and
efforts should continue with trying to make this feasible. For
example, to deﬁne signalling pathways important in determining
CPC fate choice, a pure population of CPCs would have the advantage
of offering a deﬁned extracellular environment in which to identify
candidate agonists or antagonists. In terms of genetic manipulation,
introducing transgenes or shRNA constructs in PSCs frequently leads
to silencing during differentiation, whereas starting at the CPC stage
should permit more consistent expression and could also allow the
selection and expansion (and banking) of the best population. For
disease modelling studies, having a bank of well characterized CPCs
derived from mutant and control iPSCs/ESCs could greatly improve
consistency in downstream measurements.
So what might be the factors preventing the expansion/mainte-
nance of CPCs? One factor might be the developmental state. Most
studies have focused on Isl1 and Nkx2-5-expressing cells, and it may be
that cells at this stage are already engaging cell cycle arrest mechan-
isms and be naturally and inevitably progressing towards differentia-
tion. Both of these genes regulate structural myocardial genes and so
one would expect that their expression might at least need to be kept
low to permit stable CPC proliferation. Supporting this hypothesis is
data showing a negative feedback loop on CPC gene expression
initiated by Nkx2-5 and a negative effect for Isl1 on CPC proliferation
(Kwon et al., 2009; Prall et al., 2007). Indeed, the pro-proliferative effect
of Wnt/β-catenin signalling on CPCs has been suggested to partly act
through downregulation of Isl1 (Kwon et al., 2009). So looking at the
proliferative potential of earlier developmental states may be more
productive, although the lack of deﬁnitive markers for these stages as
discussed earlier currently makes this challenging.
Identifying the optimal culture conditions will be important,
and insufﬁcient attention has been paid so far to the mitogens and
morphogens already studied in the heart development ﬁeld, as
outlined in the section above, principally concerning FGF, BMP,
SHH, IGF and Wnt. A combination of mitogenic stimulation and
repressed differentiation signalling will be required to maintain
cells in this transitional state. The correct extracellular matrix
proteins may be important, just as it is for pluripotent cells, and
the substrate stiffness can also be an important factor in regulating
cell identity (Wells, 2008). Culture at physiological oxygen tension
can improve the maintenance of stem cells and low oxygen
conditions have already been shown to improve heart derived
progenitor function (Ezashi et al., 2005; Van Oorschot et al., 2011).
To facilitate the maintenance of primary neural stem/progenitor
cells, conditional overexpression of a Myc transgene has been
employed (Kim et al., 2011), and one could envision a similar system
being helpful for CPCmaintenance at least to aid in the identiﬁcation of
the required culture conditions. Alternatively, speciﬁc cell cycle arrest
mechanisms could be identiﬁed and these genes manipulated directly.
Such a pragmatic approach could at least help to create a deﬁned
system to better understand CPC identity and help take us towards
practical uses for these enigmatic yet potentially highly valuable cells.
Summary
PSC-derived CPCs have so far remained a transient and ill-deﬁned
cell population and this has hampered a thorough characterization of
developmental patterning and cardiac cell fate decisions, as well as
the practical opportunities for the system. Enormous beneﬁt would
be gained from the development of a human cardiac cell lineage fate
map, with markers to identify cells at each stage, and a clear
understanding of the signals and mechanisms regulating each
transition. In this review we have aimed to highlight the wealth of
knowledge from developmental studies in model organisms that
should be used to help us address this challenge. However, the
underlying message is that the exact genes conferring cardiac
potential on CPCs still remain unknown and it is likely that some
critical regulators of cardiac lineage commitment have not yet been
identiﬁed. The human PSC system offers a tractable platform for
identifying or conﬁrming the human determinants, which should
advance our control of cardiomyocyte differentiation and take us one
step closer to therapeutic interventions for heart disease.
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Table 1
A summary of literature describing the expansion and differentiation of PSC-derived CPCs. Abbreviations: CM¼cardiomyocyte; SM¼smooth muscle cell; EC¼endothelial
cell; ND¼not described; CMC¼cardiac mesenchymal cells; KSR¼knockout serum replacement; LI-BPEL¼ low insulin, BSA, PVA, essential lipids; IQ1¼wnt modulator.
Publication Progenitor cell type/marker
(s)
Differentiation
potential
Expandability
(in vitro)
Culture conditions Clonality Species
Moretti et al.,
2006
Isl1þ CM, SM, EC Single expansion CMCþDMEM/F12þB27þEGF Yes Mouse
Kattman et al.,
2006
Flk1þ CM, SM, EC Passaged once StemPro34þVEGFþbFGFþBMP4þDKK ND Mouse
Wu et al., 2006 NKX2-5þ CM, SM ND ND Yes Mouse
Qyang et al.,
2007
Isl1þ CM, SM Single expansion Wnt3a-producing feeders or GSK inhibitor ND Mouse
Yang et al., 2008 KDRlow CM (50%), SM, EC
(30%)
Single expansion StemPro34þVEGFþDKKþ(bFGF) Yes Human
Bu et al., 2009 Isl1þ CM, SM, EC Single expansion Wnt3a-producing feedersþDMEM/F12þ5%
KSRþB27þbFGFþEGF
Yes Human
Domian et al.,
2009
Isl1þ/NKX2-5þ CM, SM 4-fold ND ND Mouse
Moretti et al.,
2010
Isl1þ CM, SM, EC ND RPMI/B27þVEGF ND Human
Elliott et al., 2011 NKX2-5þ CM, SM, EC Single expansion LI-BPELþPDGFαþPDGFβþWnt3AþVEGFþbFGFþBMP4 Yes Human
Nsair et al., 2012 Flt1þ/Flt4þ CM, SM, EC Passaged once ESGROþ IQ1þROCK inhibitor Yes Mouse
Ardehali et al.,
2013
KDRþ/PDGFRαþ/ROR2þ/
CD13þ
CM, SM, EC Single expansion StemPro34þFGF8þWnt11þROCK inhibitor Yes Human
M.J. Birket, C.L. Mummery / Developmental Biology 400 (2015) 169–179176
References
Adler, E.D., Goldﬁnger, J.Z., Kalman, J., Park, M.E., Meier, D.E., 2009. Palliative care in
the treatment of advanced heart failure. Circulation 120, 2597–2606.
Afouda, B.A., Martin, J., Liu, F., Ciau-Uitz, A., Patient, R., Hoppler, S, 2008. GATA
transcription factors integrate Wnt signalling during heart. Development 135,
3185–3190.
Alsan, B.H., Schultheiss, T.M., 2002. Regulation of avian cardiogenesis by Fgf8
signaling. Development 129, 1935–1943.
Ardehali, R., Ali, S.R., Inlay, M.A., Abilez, O.J., Chen, M.Q., Blauwkamp, T.A., Yazawa,
M., Gong, Y., Nusse, R., Drukker, M., et al., 2013. Prospective isolation of human
embryonic stem cell-derived cardiovascular progenitors that integrate into
human fetal heart tissue. Proc. Natl. Acad. Sci. USA 110, 3405–3410.
Baker, J., Liu, J.-P., Robertson, E.J., Efstratiadis, A., 1993. Role of insulin-like growth
factors in embryonic and postnatal growth. Cell 75, 73–82.
Barker, N., Bartfeld, S., Clevers, H., 2010. Tissue-resident adult stem cell populations
of rapidly self-renewing organs. Cell Stem Cell 7, 656–670.
Beachy, P.A., Karhadkar, S.S., Berman, D.M., 2004. Tissue repair and stem cell
renewal in carcinogenesis. Nature 432, 324–331.
Bearzi, C., Rota, M., Hosoda, T., Tillmanns, J., Nascimbene, A., De Angelis, A.,
Yasuzawa-Amano, S., Troﬁmova, I., Siggins, R.W., LeCapitaine, N., et al., 2007.
Human cardiac stem cells. Proc. Natl. Acad. Sci. USA 104, 14068–14073.
Beltrami, A.P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., Kasahara,
H., Rota, M., Musso, E., Urbanek, K., et al., 2003. Adult cardiac stem cells are
multipotent and support myocardial regeneration. Cell 114, 763–776.
Bergmann, O., Bhardwaj, R.D., Bernard, S., Zdunek, S., Barnabe-Heider, F., Walsh, S.,
Zupicich, J., Alkass, K., Buchholz, B.A., Druid, H., et al., 2009. Evidence for
cardiomyocyte renewal in humans. Science 324, 98–102.
Bertocchini, F., Skromne, I., Wolpert, L., Stern, C.D., 2004. Determination of
embryonic polarity in a regulative system: evidence for endogenous inhibitors
acting sequentially during primitive streak formation in the chick embryo.
Development 131, 3381–3390.
Birket, M.J., Casini, S., Kosmidis, G., Elliott, D.A., Gerencser, A.A., Baartscheer, A.,
Schumacher, C., Mastroberardino, P.G., Elefanty, A.G., Stanley, E.G., et al., 2013.
PGC-1? and reactive oxygen species regulate human embryonic stem cell-
derived cardiomyocyte function. Stem Cell Rep. 1, 560–574.
Bu, L., Jiang, X., Martin-Puig, S., Caron, L., Zhu, S., Shao, Y., Roberts, D.J., Huang, P.L.,
Domian, I.J., Chien, K.R., 2009. Human ISL1 heart progenitors generate diverse
multipotent cardiovascular cell lineages. Nature 460, 113–117.
Buckingham, M., Meilhac, S., Zaffran, S., 2005. Building the mammalian heart from
two sources of myocardial cells. Nat. Rev. Genet. 6, 826–835.
Cai, C.-L., Liang, X., Shi, Y., Chu, P.-H., Pfaff, S.L., Chen, J., Evans, S., 2003. Isl1
identiﬁes a cardiac progenitor population that proliferates prior to differentia-
tion and contributes a majority of cells to the heart. Dev. Cell 5, 877–889.
Cai, W., Albini, S., Wei, K., Willems, E., Guzzo, R.M., Tsuda, M., Giordani, L., Spiering,
S., Kurian, L., Yeo, G.W., et al., 2013. Coordinate nodal and BMP inhibition directs
Baf60c-dependent cardiomyocyte commitment. Genes Dev. 27, 2332–2344.
Cheng, X., Ying, L., Lu, L., Galvao, A.M., Mills, J.A., Lin, H.C., Kotton, D.N., Shen, S.S.,
Nostro, M.C., Choi, J.K., et al., 2012. Self-renewing endodermal progenitor lines
generated from human pluripotent stem cells. Cell Stem Cell 10, 371–384.
Cheng, X., Tiyaboonchai, A., Gadue, P., 2013. Endodermal stem cell populations
derived from pluripotent stem cells. Curr. Opin. Cell Biol. 25, 265–271.
Christoffels, V.M., Smits, G.J., Kispert, A., Moorman, A.F.M., 2010. Development of
the pacemaker tissues of the heart. Circ. Res. 106, 240–254.
Cohen, E.D., Wang, Z., Lepore, J.J., Lu, M.M., Taketo, M.M., Epstein, D.J., Morrisey, E.E.,
2007. Wnt/β-catenin signaling promotes expansion of Isl-1–positive cardiac
progenitor cells through regulation of FGF signaling. J. Clin. Invest. 117,
1794–1804.
Cohen, E.D., Miller, M.F., Wang, Z., Moon, R.T., Morrisey, E.E., 2012. Wnt5a and
Wnt11 are essential for second heart ﬁeld progenitor development. Develop-
ment 139, 1931–1940.
D’Amario, D., Cabral-Da-Silva, M.C., Zheng, H., Fiorini, C., Goichberg, P., Steadman,
E., Ferreira-Martins, J., Sanada, F., Piccoli, M., Cappetta, D., et al., 2011. Insulin-
like growth factor-1 receptor identiﬁes a pool of human cardiac stem cells with
superior therapeutic potential for myocardial regeneration. Circ. Res. 108,
1467–1481.
Darabi, R., Arpke, R.W., Irion, S., Dimos, J.T., Grskovic, M., Kyba, M., Perlingeiro, R.C.
R., 2012. Human ES- and iPS-derived myogenic progenitors restore DYSTRO-
PHIN and improve contractility upon transplantation in dystrophic mice. Cell
Stem Cell 10, 610–619.
Devine, W.P., Wythe, J.D., George, M., Koshiba-Takeuchi, K., Bruneau, B.G., 2014.
Early patterning and speciﬁcation of cardiac progenitors in gastrulating
mesoderm. eLife 3, e03848.
Doherty, K.R., Wappel, R.L., Talbert, D.R., Trusk, P.B., Moran, D.M., Kramer, J.W.,
Brown, A.M., Shell, S.A., Bacus, S., 2013. Multi-parameter in vitro toxicity testing
of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Toxicol. Appl. Pharmacol. 272, 245–255.
Domian, I.J., Chiravuri, M., van der Meer, P., Feinberg, A.W., Shi, X., Shao, Y., Wu, S.
M., Parker, K.K., Chien, K.R., 2009. Generation of functional ventricular heart
muscle from mouse ventricular progenitor cells. Science 326, 426–429.
Drawnel, F.M., Boccardo, S., Prummer, M., Delobel, F., Graff, A., Weber, M., Gérard, R.,
Badi, L., Kam-Thong, T., Bu, L., et al., 2014. Disease modeling and phenotypic
drug screening for diabetic cardiomyopathy using human induced pluripotent
stem cells. Cell Rep. 9, 810–820.
Drysdale, T.A., Patterson, K.D., Saha, M., Krieg, P.A., 1997. Retinoic acid can block
differentiation of the myocardium after heart speciﬁcation. Dev. Biol. 188,
205–215.
Dubois, N.C., Craft, A.M., Sharma, P., Elliott, D.A., Stanley, E.G., Elefanty, A.G.,
Gramolini, A., Keller, G., 2011. SIRPA is a speciﬁc cell-surface marker for
isolating cardiomyocytes derived from human pluripotent stem cells. Nat.
Biotechnol. 29, 1011–1018.
Dyer, L.A., Makadia, F.A., Scott, A., Pegram, K., Hutson, M.R., Kirby, M.L., 2010. BMP
signaling modulates hedgehog-induced secondary heart ﬁeld proliferation.
Dev. Biol. 348, 167–176.
Elliott, D.A., Braam, S.R., Koutsis, K., Ng, E.S., Jenny, R., Lagerqvist, E.L., Biben, C.,
Hatzistavrou, T., Hirst, C.E., Yu, Q.C., et al., 2011. NKX2-5eGFP/w hESCs for
isolation of human cardiac progenitors and cardiomyocytes. Nat. Methods 8,
1037–1040.
Ezashi, T., Das, P., Roberts, R.M., 2005. Low O2 tensions and the prevention of
differentiation of hES cells. Proc. Natl. Acad. Sci. USA 102, 4783–4788.
Gage, F.H., Temple, S., 2013. Neural stem cells: generating and regenerating the
brain. Neuron 80, 588–601.
Galli, D., Domínguez, J.N., Zaffran, S., Munk, A., Brown, N.A., Buckingham, M.E.,
2008. Atrial myocardium derives from the posterior region of the second heart
ﬁeld, which acquires left-right identity as Pitx2c is expressed. Development
135, 1157–1167.
Garcia-Frigola, C., Shi, Y., Evans, S.M., 2003. Expression of the hyperpolarization-
activated cyclic nucleotide-gated cation channel HCN4 during mouse heart
development. Gene Expr. Patterns 3, 777–783.
Gittenberger‐De Groot, A.C., Mahtab, E.A.F., Hahurij, N.D., Wisse, L.J., Deruiter, M.C.,
Wijffels, M.C.E., Poelmann, R.E, 2007. Nkx2.5‐negative myocardium of the
posterior heart ﬁeld and its correlation with podoplanin expression in cells
from the developing cardiac pacemaking and conduction system. Anat. Rec.
290, 115–122.
Goddeeris, M.M., Schwartz, R., Klingensmith, J., Meyers, E.N., 2007. Independent
requirements for Hedgehog signaling by both the anterior heart ﬁeld and
neural crest cells for outﬂow tract. Development 134, 1593–1604.
Goumans, M.-J., de Boer, T.P., Smits, A.M., van Laake, L.W., van Vliet, P., Metz, C.H.G.,
Korfage, T.H., Kats, K.P., Hochstenbach, R., Pasterkamp, G., et al., 2008. TGF-β1
induces efﬁcient differentiation of human cardiomyocyte progenitor cells into
functional cardiomyocytes in vitro. Stem Cell Res. 1, 138–149.
Gude, N., Muraski, J., Rubio, M., Kajstura, J., Schaefer, E., Anversa, P., Sussman, M.A.,
2006. Akt promotes increased cardiomyocyte cycling and expansion of the
cardiac progenitor cell population. Circ. Res. 99, 381–388.
Hami, D., Grimes, A.C., Tsai, H.-J., Kirby, M.L., 2011. Zebraﬁsh cardiac development
requires a conserved secondary heart ﬁeld. Development 138, 2389–2398.
Den Hartogh, S.C., Schreurs, C., Monshouwer-Kloots, J.J., Davis, R.P., Elliott, D.A.,
Mummery, C., Passier, R., 2015. Dual reporter MESP1mCherry/w-NKX2-5eGFP/
w hESCs enable studying early human cardiac differentiation. Stem Cells 33,
56–67.
Hoffmann, A.D., Peterson, M.A., Friedland-Little, J.M., Anderson, S.A., Moskowitz, I.P.,
2009. Sonic hedgehog is required in pulmonary endoderm for atrial septation.
Development 136, 1761–1770.
Hutson, M.R., Zeng, X.L., Kim, A.J., Antoon, E., Harward, S., Kirby, M.L., 2010. Arterial
pole progenitors interpret opposing FGF/BMP signals to proliferate or differ-
entiate. Development 137, 3001–3011.
Ilagan, R., Abu-Issa, R., Brown, D., Yang, Y.-P., Jiao, K., Schwartz, R.J., Klingensmith, J.,
Meyers, E.N., 2006. Fgf8 is required for anterior heart ﬁeld. Development 133,
2435–2445.
Ionta, V., Liang, W., Kim, E.H., Raﬁe, R., Giacomello, A., Marbán, E., Cho, H.C., 2015.
SHOX2 overexpression favors differentiation of embryonic stem cells into
cardiac pacemaker cells, improving biological pacing ability. Stem Cell Rep. 4
(1), 129–142.
Jain, M., Rivera, S., Monclus, E.A., Synenki, L., Zirk, A., Eisenbart, J., Feghali-Bostwick, C.,
Mutlu, G.M., Budinger, G.R.S., Chandel, N.S., 2013. Mitochondrial reactive oxygen
species regulate TGF-beta signaling. J. Biol. Chem. 228, 770–777.
Jessberger, S., Gage, F.H., 2014. Adult neurogenesis: bridging the gap between mice
and humans. Trends Cell Biol. 24, 558–563.
Jesty, S.A., Steffey, M.A., Lee, F.K., Breitbach, M., Hesse, M., Reining, S., Lee, J.C.,
Doran, R.M., Nikitin, A.Y., Fleischmann, B.K., et al., 2012. c-kitþprecursors
support postinfarction myogenesis in the neonatal, but not adult, heart. Proc.
Natl. Acad. Sci. USA 109, 13380–13385.
Jung, J.J., Husse, B., Rimmbach, C., Krebs, S., Stieber, J., Steinhoff, G., Dendorfer, A.,
Franz, W.-M., David, R., 2014. Programming and isolation of highly pure
physiologically and pharmacologically functional sinus-nodal bodies from
pluripotent stem cells. Stem Cell Rep. 2, 592–605.
Kataoka, H., Takakura, N., Nishikawa, S., Tsuchida, K., Kodama, H., Kunisada, T.,
Risau, W., Kita, T., Nishikawa, S.I., 1997. Expressions of PDGF receptor alpha, c-
Kit and Flk1 genes clustering in mouse chromosome 5 deﬁne distinct subsets of
nascent mesodermal cells. Dev. Growth Differ. 39, 729–740.
Kattman, S.J., Huber, T.L., Keller, G.M., 2006. Multipotent Flk-1þcardiovascular
progenitor cells give rise to the cardiomyocyte, endothelial, and vascular
smooth muscle lineages. Dev. Cell 11, 723–732.
Kattman, S.J., Witty, A.D., Gagliardi, M., Dubois, N.C., Niapour, M., Hotta, A., Ellis, J.,
Keller, G., 2011. Stage-speciﬁc optimization of activin/nodal and BMP signaling
promotes cardiac differentiation of mouse and human pluripotent stem cell
lines. Cell Stem Cell 8, 228–240.
Kempf, H., Olmer, R., Kropp, C., Rückert, M., Jara-Avaca, M., Robles-Diaz, D., Franke,
A., Elliott, D.A., Wojciechowski, D., Fischer, M., et al., 2014. Controlling
M.J. Birket, C.L. Mummery / Developmental Biology 400 (2015) 169–179 177
expansion and cardiomyogenic differentiation of human pluripotent stem cells
in scalable suspension culture. Stem Cell Rep. 3, 1132–1146.
Keren-Politansky, A., Keren, A., Bengal, E., 2009. Neural ectoderm-secreted FGF
initiates the expression of Nkx2.5 in cardiac progenitors via a p38 MAPK/CREB
pathway. Dev. Biol. 335, 374–384.
Kim, K.S., Lee, H.J., Jeong, H.S., Li, J., Teng, Y.D., Sidman, R.L., Snyder, E.Y., Kim, S.U.,
2011. Self-renewal induced efﬁciently, safely, and effective therapeutically with
one regulatable gene in a human somatic progenitor cell. Proc. Natl. Acad. Sci.
USA 108, 4876–4881.
Klaus, A., Saga, Y., Taketo, M.M., Tzahor, E., Birchmeier, W., 2007. Distinct roles of
Wnt/β-catenin and Bmp signaling during early cardiogenesis. Proc. Natl. Acad.
Sci. USA 104, 18531–18536.
Kwon, C., Qian, L., Cheng, P., Nigam, V., Arnold, J., Srivastava, D., 2009. A regulatory
pathway involving notch1/β-catenin/Isl1 determines cardiac progenitor cell
fate. Nat. Cell Biol. 11, 951–957.
Laugwitz, K.-L., Moretti, A., Lam, J., Gruber, P., Chen, Y., Woodard, S., Lin, L.-Z., Cai, C.-
L., Lu, M.M., Reth, M., et al., 2005. Postnatal isl1þcardioblasts enter fully
differentiated cardiomyocyte lineages. Nature 433, 647–653.
Lavine, K.J., Yu, K., White, A.C., Zhang, X., Smith, C., Partanen, J., Ornitz, D.M., 2005.
Endocardial and epicardial derived fgf signals regulate myocardial proliferation
and differentiation in vivo. Dev. Cell 8, 85–95.
Lescroart, F., Chabab, S., Lin, X., Rulands, S., Paulissen, C., Rodolosse, A., Auer, H.,
Achouri, Y., Dubois, C., Bondue, A., et al., 2014. Early lineage restriction in
temporally distinct populations of Mesp1 progenitors during mammalian heart
development. Nat. Cell Biol. 16, 829–840.
Li, M., Suzuki, K., Kim, N.Y., Liu, G.-H., Izpisua Belmonte, J.C., 2014. A cut above the
rest: targeted genome editing technologies in human pluripotent stem cells. J.
Biol. Chem. 289, 4594–4599.
Li, P., Cavallero, S., Gu, Y., Chen, T.H.P., Hughes, J., Hassan, A.B., Brüning, J.C.,
Pashmforoush, M., Sucov, H.M., 2011. IGF signaling directs ventricular cardio-
myocyte proliferation during embryonic heart. Development 138, 1795–1805.
Lian, X., Zhang, J., Azarin, S.M., Zhu, K., Hazeltine, L.B., Bao, X., Hsiao, C., Kamp, T.J.,
Palecek, S.P., 2013. Directed cardiomyocyte differentiation from human plur-
ipotent stem cells by modulating Wnt/β-catenin signaling under fully deﬁned
conditions. Nat. Protoc. 8, 162–175.
Liang, X., Wang, G., Lin, L., Lowe, J., Zhang, Q., Bu, L., Chen, Y., Chen, J., Sun, Y., Evans,
S.M., 2013. HCN4 dynamically marks the ﬁrst heart ﬁeld and conduction system
precursors. Circ. Res. 113, 399–407.
Liberatore, C.M., Searcy-Schrick, R.D., Vincent, E.B., Yutzey, K.E., 2002. Nkx-2.5 gene
induction in mice is mediated by a smad consensus regulatory region. Dev. Biol.
244, 243–256.
Lickert, H., Takeuchi, J.K., von Both, I., Walls, J.R., McAuliffe, F., Lee Adamson, S., Mark
Henkelman, R., Wrana, J.L., Rossant, J., Bruneau, B.G., 2004. Baf60c is essential
for function of BAF chromatin remodelling complexes in heart development.
Nature 432, 107–112.
Lien, C.-L., McAnally, J., Richardson, J.A., Olson, E.N., 2002. Cardiac-speciﬁc activity
of an Nkx2.5 enhancer requires an evolutionarily conserved smad binding site.
Dev. Biol. 244, 257–266.
Lin, Q., Schwarz, J., Bucana, C., Olson, E.N., 1997. Control of mouse cardiac
morphogenesis and myogenesis by transcription factor MEF2C. Science 276,
1404–1407.
Lloyd-Jones, D., Adams, R.J., Brown, T.M., Carnethon, M., Dai, S., Simone, G.D.,
Ferguson, T.B., Ford, E., Furie, K., Gillespie, C., et al., 2010. Heart disease and
stroke statistics—2010 update: a report from the American Heart Association.
Circulation 121, e46–e215.
Lou, X., Deshwar, A.R., Crump, J.G., Scott, I.C., 2011. Smarcd3b and Gata5 promote a
cardiac progenitor fate in the zebraﬁsh embryo. Development 138, 3113–3123.
Lyons, I., Parsons, L.M., Hartley, L., Li, R., Andrews, J.E., Robb, L., Harvey, R.P., 1995.
Myogenic and morphogenetic defects in the heart tubes of murine embryos
lacking the homeo box gene Nkx2-5. Genes Dev. 9, 1654–1666.
Ma, Q., Zhou, B., Pu, W.T., 2008. Reassessment of Isl1 and Nkx2–5 cardiac fate maps
using a Gata4-based reporter of Cre activity. Dev. Biol. 323, 98–104.
Macatee, T.L., Hammond, B.P., Arenkiel, B.R., Francis, L., Frank, D.U., Moon, A.M.,
2003. Ablation of speciﬁc expression domains reveals discrete functions of
ectoderm- and endoderm-derived FGF8 during cardiovascular and pharyngeal.
Development 130, 6361–6374.
Madhala-Levy, D., Williams, V., Hughes, S., Reshef, R., Halevy, O., 2012. Cooperation
between Shh and IGF-I in promoting myogenic proliferation and differentiation
via the MAPK/ERK and PI3K/Akt pathways requires smo activity. J. Cell. Physiol.
227, 1455–1464.
Marguerie, A., Bajolle, F., Zaffran, S., Brown, N.A., Dickson, C., Buckingham, M.E.,
Kelly, R.G., 2006. Congenital heart defects in Fgfr2-IIIb and Fgf10 mutant mice.
Cardiovasc. Res. 71, 50–60.
Marques, S.R., Yelon, D., 2009. Differential requirement for BMP signaling in atrial
and ventricular lineages establishes cardiac chamber proportionality. Dev. Biol.
328, 472–482.
Martin, C.M., Meeson, A.P., Robertson, S.M., Hawke, T.J., Richardson, J.A., Bates, S.,
Goetsch, S.C., Gallardo, T.D., Garry, D.J., 2004. Persistent expression of the ATP-
binding cassette transporter, Abcg2, identiﬁes cardiac SP cells in the developing
and adult heart. Dev. Biol. 265, 262–275.
Martin, J., Afouda, B.A., Hoppler, S., 2010. Wnt/β-catenin signalling regulates
cardiomyogenesis via GATA transcription factors. J. Anat. 216, 92–107.
Matsa, E., Burridge, P.W., Wu, J.C., 2014. Human stem cells for modeling heart
disease and for drug discovery. Sci. Transl. Med. 6, 239ps6.
Meilhac, S.M., Kelly, R.G., Rocancourt, D., Eloy-Trinquet, S., Nicolas, J-F., Buckingham,
M.E., 2003. A retrospective clonal analysis of the myocardium reveals two
phases of clonal growth in the developing mouse heart. Development 130,
3877–3889.
Meilhac, S.M., Esner, M., Kelly, R.G., Nicolas, J.-F., Buckingham, M.E., 2004. The
clonal origin of myocardial cells in different regions of the embryonic mouse
heart. Dev. Cell 6, 685–698.
Mercola, M., Ruiz-Lozano, P., Schneider, M.D., 2011. Cardiac muscle regeneration:
lessons from development. Genes Dev. 25, 299–309.
Messina, E., Angelis, L.D., Frati, G., Morrone, S., Chimenti, S., Fiordaliso, F., Salio, M.,
Battaglia, M., Latronico, M.V.G., Coletta, M., et al., 2004. Isolation and expansion
of adult cardiac stem cells from human and murine heart. Circ. Res. 95,
911–921.
Mommersteeg, M.T.M., Hoogaars, W.M.H., Prall, O.W.J., Vries, C. de G., Wiese, C.,
Clout, D.E.W., Papaioannou, V.E., Brown, N.A., Harvey, R.P., Moorman, A.F.M.,
et al., 2007. Molecular pathway for the localized formation of the sinoatrial
node. Circ. Res. 100, 354–362.
Moretti, A., Caron, L., Nakano, A., Lam, J.T., Bernshausen, A., Chen, Y., Qyang, Y., Bu,
L., Sasaki, M., Martin-Puig, S., et al., 2006. Multipotent embryonic isl1þpro-
genitor cells lead to cardiac, smooth muscle, and endothelial cell diversiﬁcation.
Cell 127, 1151–1165.
Moretti, A., Bellin, M., Jung, C.B., Thies, T.-M., Takashima, Y., Bernshausen, A.,
Schiemann, M., Fischer, S., Moosmang, S., Smith, A.G., et al., 2010. Mouse and
human induced pluripotent stem cells as a source for multipotent
Isl1þcardiovascular progenitors. FASEB J. 24, 700–711.
Motoike, T., Markham, D.W., Rossant, J., Sato, T.N., 2003. Evidence for novel fate of
Flk1þprogenitor: contribution to muscle lineage. Genesis 35, 153–159.
Mummery, C.L., Lee, R.T., 2013. Is heart regeneration on the right track? Nat. Med.
19, 412–413.
Nadal-Ginard, B., Ellison, G.M., Torella, D., 2014. Response to Molkentin's Letter to
the editor regarding article, “The Absence of Evidence Is Not Evidence of
Absence: the Pitfalls of Cre Knock-Ins in the c-kit Locus. Circ. Res. 115, e38–e39.
Naito, A.T., Shiojima, I., Akazawa, H., Hidaka, K., Morisaki, T., Kikuchi, A., Komuro, I.,
2006. Developmental stage-speciﬁc biphasic roles of Wnt/β-catenin signaling
in cardiomyogenesis and hematopoiesis. Proc. Natl. Acad. Sci. USA 103,
19812–19817.
Nakamura, S., Takayama, N., Hirata, S., Seo, H., Endo, H., Ochi, K., Fujita, K., Koike, T.,
Harimoto, K., Dohda, T., et al., 2014. Expandable megakaryocyte cell lines enable
clinically applicable generation of platelets from human induced pluripotent
stem cells. Cell Stem Cell 14, 535–548.
Noack, C., Zaﬁriou, M.-P., Schaeffer, H.-J., Renger, A., Pavlova, E., Dietz, R., Zimmer-
mann, W.H., Bergmann, M.W., Zelarayán, L.C., 2012. Krueppel‐like factor 15
regulates Wnt/β‐catenin transcription and controls cardiac progenitor cell fate
in the postnatal heart. EMBO Mol. Med. 4, 992–1007.
Novikov, N., Evans, T., 2013. Tmem88a mediates GATA-dependent speciﬁcation of
cardiomyocyte progenitors by restricting WNT signaling. Development 140,
3787–3798.
Nsair, A., Schenke-Layland, K., Van Handel, B., Evseenko, D., Kahn, M., Zhao, P.,
Mendelis, J., Heydarkhan, S., Awaji, O., Vottler, M., et al., 2012. Characterization
and therapeutic potential of induced pluripotent stem cell-derived cardiovas-
cular progenitor cells. PLoS One, 7.
Oh, H., Bradfute, S.B., Gallardo, T.D., Nakamura, T., Gaussin, V., Mishina, Y., Pocius, J.,
Michael, L.H., Behringer, R.R., Garry, D.J., et al., 2003. Cardiac progenitor cells
from adult myocardium: homing, differentiation, and fusion after infarction.
Proc. Natl. Acad. Sci. USA 100, 12313–12318.
Okabe, S., Forsberg-Nilsson, K., Spiro, A.C., Segal, M., McKay, R.D.G., 1996. Devel-
opment of neuronal precursor cells and functional postmitotic neurons from
embryonic stem cells in vitro. Mech. Dev. 59, 89–102.
Palpant, N.J., Pabon, L., Rabinowitz, J.S., Hadland, B.K., Stoick-Cooper, C.L., Paige, S.L.,
Bernstein, I.D., Moon, R.T., Murry, C.E., 2013. Transmembrane protein 88: a Wnt
regulatory protein that speciﬁes cardiomyocyte. Development 140, 3799–3808.
Park, E.J., Ogden, L.A., Talbot, A., Evans, S., Cai, C.-L., Black, B.L., Frank, D.U., Moon, A.M.,
2006. Required, tissue-speciﬁc roles for Fgf8 in outﬂow tract formation and
remodeling. Development 133, 2419–2433.
Pater, E. de, Ciampricotti, M., Priller, F., Veerkamp, J., Strate, I., Smith, K., Lagendijk, A.K.,
Schilling, T.F., Herzog, W., Abdelilah-Seyfried, S., et al., 2012. Bmp signaling exerts
opposite effects on cardiac differentiation. Circ. Res. 110, 578–587.
Porrello, E.R., Mahmoud, A.I., Simpson, E., Hill, J.A., Richardson, J.A., Olson, E.N.,
Sadek, H.A., 2011. Transient regenerative potential of the neonatal mouse heart.
Science 331, 1078–1080.
Prall, O.W.J., Menon, M.K., Solloway, M.J., Watanabe, Y., Zaffran, S., Bajolle, F., Biben, C.,
McBride, J.J., Robertson, B.R., Chaulet, H., et al., 2007. An Nkx2-5/Bmp2/Smad1
negative feedback loop controls heart progenitor speciﬁcation and proliferation.
Cell 128, 947–959.
Puente, B.N., Kimura, W., Muralidhar, S.A., Moon, J., Amatruda, J.F., Phelps, K.L.,
Grinsfelder, D., Rothermel, B.A., Chen, R., Garcia, J.A., et al., 2014. The oxygen-
rich postnatal environment induces cardiomyocyte cell-cycle arrest through
DNA damage response. Cell 157, 565–579.
Qyang, Y., Martin-Puig, S., Chiravuri, M., Chen, S., Xu, H., Bu, L., Jiang, X., Lin, L.,
Granger, A., Moretti, A., et al., 2007. The renewal and differentiation of Isl1þ
cardiovascular progenitors are controlled by a Wnt/Î2-catenin pathway. Cell
Stem Cell 1, 165–179.
Ran, D., Shia, W.-J., Lo, M.-C., Fan, J.-B., Knorr, D.A., Ferrell, P.I., Ye, Z., Yan, M., Cheng, L.,
Kaufman, D.S., et al., 2013. RUNX1a enhances hematopoietic lineage commit-
ment from human embryonic stem cells and inducible pluripotent stem cells.
Blood 121, 2882–2890.
M.J. Birket, C.L. Mummery / Developmental Biology 400 (2015) 169–179178
Reifers, F., Walsh, E.C., Leger, S., Stainier, D.Y., Brand, M., 2000. Induction and
differentiation of the zebraﬁsh heart requires ﬁbroblast growth factor 8 (fgf8/
acerebellar). Development 127, 225–235.
Reubinoff, B.E., Itsykson, P., Turetsky, T., Pera, M.F., Reinhartz, E., Itzik, A., Ben-Hur, T.,
2001. Neural progenitors from human embryonic stem cells. Nat. Biotechnol. 19,
1134–1140.
Riobó, N.A., Lu, K., Ai, X., Haines, G.M., Emerson, C.P., 2006. Phosphoinositide
3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc. Natl. Acad.
Sci. USA 103, 4505–4510.
Saga, Y., Miyagawa-Tomita, S., Takagi, A., Kitajima, S., Miyazaki, J.i, Inoue, T., 1999.
MesP1 is expressed in the heart precursor cells and required for the formation
of a single heart tube. Development 126, 3437–3447.
Scott, I.C., 2012. Chapter one – life before Nkx2.5: Cardiovascular progenitor cells:
embryonic origins and development. In: Bruneau, Benoit G. (Ed.), Current
Topics in Developmental Biology. Elsevier, pp. 1–31.
Serna, I.L. de la, Ohkawa, Y., Berkes, C.A., Bergstrom, D.A., Dacwag, C.S., Tapscott, S.J.,
Imbalzano, A.N., 2005. MyoD targets chromatin remodeling complexes to the
myogenin locus prior to forming a stable DNA-bound complex. Mol. Cell. Biol.
25, 3997–4009.
Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D.,
Ebert, B.L., Root, D.E., Doench, J.G., et al., 2014. Genome-scale CRISPR-Cas9
knockout screening in human cells. Science 343, 84–87.
Sinha, S., Iyer, D., Granata, A., 2014. Embryonic origins of human vascular smooth
muscle cells: implications for in vitro modeling and clinical application. Cell.
Mol. Life Sci. 71, 2271–2288.
Sirbu, I.O., Zhao, X., Duester, G., 2008. Retinoic acid controls heart anteroposterior
patterning by downregulating Isl1 through the Fgf8 pathway. Dev. Dyn. 237,
1627–1635.
Skelton, R.J.P., Costa, M., Anderson, D.J., Bruveris, F., Finnin, B.W., Koutsis, K.,
Arasaratnam, D., White, A.J., Raﬁi, A., Ng, E.S., et al., 2014. SIRPA, VCAM1 and
CD34 identify discrete lineages during early human cardiovascular develop-
ment. Stem Cell Res. 13, 172–179.
Sneddon, J.B., Borowiak, M., Melton, D.A., 2012. Self-renewal of embryonic-stem-
cell-derived progenitors by organ-matched mesenchyme. Nature 491, 765–768.
Später, D., Abramczuk, M.K., Buac, K., Zangi, L., Stachel, M.W., Clarke, J., Sahara, M.,
Ludwig, A., Chien, K.R., 2013. A HCN4þcardiomyogenic progenitor derived from
the ﬁrst heart ﬁeld and human pluripotent stem cells. Nat. Cell Biol. 15,
1098–1106.
Sun, X., Meyers, E.N., Lewandoski, M., Martin, G.R., 1999. Targeted disruption of Fgf8
causes failure of cell migration in the gastrulating mouse embryo. Genes Dev.
13, 1834–1846.
Takeuchi, J.K., Bruneau, B.G., 2009. Directed transdifferentiation of mouse meso-
derm to heart tissue by deﬁned factors. Nature 459, 708–711.
Thavandiran, N., Dubois, N., Mikryukov, A., Massé, S., Beca, B., Simmons, C.A.,
Deshpande, V.S., McGarry, J.P., Chen, C.S., Nanthakumar, K., et al., 2013. Design
and formulation of functional pluripotent stem cell-derived cardiac microtis-
sues. Proc. Natl. Acad. Sci. USA 110, E4698–E4707.
Thomas, N.A., Koudijs, M., Eeden, F.J.M., van, Joyner, A.L., Yelon, D., 2008. Hedgehog
signaling plays a cell-autonomous role in maximizing cardiac developmental
potential. Development 135, 3789–3799.
Van Berlo, J.H., Molkentin, J.D., 2014. An emerging consensus on cardiac regenera-
tion. Nat. Med. 20, 1386–1393.
Van Berlo, J.H., Kanisicak, O., Maillet, M., Vagnozzi, R.J., Karch, J., Lin, S.-C.J.,
Middleton, R.C., Marbán, E., Molkentin, J.D., 2014. c-kitþ cells minimally
contribute cardiomyocytes to the heart. Nature 509, 337–341.
Van Oorschot, A.A.M., Smits, A.M., Pardali, E., Doevendans, P.A., Goumans, M.-J.,
2011. Low oxygen tension positively inﬂuences cardiomyocyte progenitor cell
function. J. Cell. Mol. Med. 15, 2723–2734.
Vlad, A., Röhrs, S., Klein-Hitpass, L., Müller, O., 2008. The ﬁrst ﬁve years of the Wnt
targetome. Cell Signal. 20, 795–802.
Wang, G., McCain, M.L., Yang, L., He, A., Pasqualini, F.S., Agarwal, A., Yuan, H., Jiang, D.,
Zhang, D., Zangi, L., et al., 2014a. Modeling the mitochondrial cardiomyopathy of
Barth syndrome with induced pluripotent stem cell and heart-on-chip technol-
ogies. Nat. Med. 20, 616–623.
Wang, T., Wei, J.J., Sabatini, D.M., Lander, E.S., 2014b. Genetic screens in human cells
using the CRISPR-Cas9 system. Science 343, 80–84.
Waring, C.D., Vicinanza, C., Papalamprou, A., Smith, A.J., Purushothaman, S., Gold-
spink, D.F., Nadal-Ginard, B., Torella, D., Ellison, G.M., 2014. The adult heart
responds to increased workload with physiologic hypertrophy, cardiac stem cell
activation, and new myocyte formation. Eur. Heart J. 35, 2722–2731.
Watanabe, Y., Miyagawa-Tomita, S., Vincent, S.D., Kelly, R.G., Moon, A.M., Bucking-
ham, M.E., 2010. Role of mesodermal FGF8 and FGF10 overlaps in the
development of the arterial pole of the heart and pharyngeal arch arteries.
Circ. Res. 106, 495–503.
Watanabe, Y., Zaffran, S., Kuroiwa, A., Higuchi, H., Ogura, T., Harvey, R.P., Kelly, R.G.,
Buckingham, M., 2012. Fibroblast growth factor 10 gene regulation in the
second heart ﬁeld by Tbx1, Nkx2-5, and Islet1 reveals a genetic switch for
down-regulation in the myocardium. Proc. Natl. Acad. Sci. USA 109,
18273–18280.
Wells, R.G., 2008. The role of matrix stiffness in regulating cell behavior. Hepatol-
ogy 47, 1394–1400.
Wiese, C., Grieskamp, T., Airik, R., Mommersteeg, M.T.M., Gardiwal, A., de G.Vries, C.,
Schuster-Gossler, K., Moorman, A.F.M., Kispert, A., Christoffels, V.M., 2009.
Formation of the sinus node head and differentiation of sinus node myocar-
dium are independently regulated by Tbx18 and Tbx3. Circ. Res. 104, 388–397.
Willems, E., Cabral-Teixeira, J., Schade, D., Cai, W., Reeves, P., Bushway, P.J., Lanier,
M., Walsh, C., Kirchhausen, T., Belmonte, J.C.I., et al., 2012. Small molecule-
mediated TGF? Type II receptor degradation promotes cardiomyogenesis in
embryonic stem cells. Cell Stem Cell 11, 242–252.
Wu, S.M., Fujiwara, Y., Cibulsky, S.M., Clapham, D.E., Lien, C., Schultheiss, T.M.,
Orkin, S.H., 2006. Developmental origin of a bipotential myocardial and smooth
muscle cell precursor in the mammalian heart. Cell 127, 1137–1150.
Yang, L., Soonpaa, M.H., Adler, E.D., Roepke, T.K., Kattman, S.J., Kennedy, M.,
Henckaerts, E., Bonham, K., Abbott, G.W., Linden, R.M., et al., 2008. Human
cardiovascular progenitor cells develop from a KDRþ embryonic-stem-cell-
derived population. Nature 453, 524–528.
Yuasa, S., Itabashi, Y., Koshimizu, U., Tanaka, T., Sugimura, K., Kinoshita, M., Hattori,
F., Fukami, S., Shimazaki, T., Ogawa, S., et al., 2005. Transient inhibition of BMP
signaling by Noggin induces cardiomyocyte differentiation of mouse embryonic
stem cells. Nat. Biotechnol. 23, 607–611.
Zaruba, M.-M., Soonpaa, M., Reuter, S., Field, L.J., 2010. Cardiomyogenic potential of
C-kit(þ)-expressing cells derived from neonatal and adult mouse hearts.
Circulation 121, 1992–2000.
Zhang, M., D’Aniello, C., Verkerk, A.O., Wrobel, E., Frank, S., Ward-van Oostwaard,
D., Piccini, I., Freund, C., Rao, J., Seebohm, G., et al., 2014. Recessive cardiac
phenotypes in induced pluripotent stem cell models of Jervell and Lange-
Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc. Natl.
Acad. Sci. USA 111, E5383–E5392.
Zhang, Q., Jiang, J., Han, P., Yuan, Q., Zhang, J., Zhang, X., Xu, Y., Cao, H., Meng, Q.,
Chen, L., et al., 2011. Direct differentiation of atrial and ventricular myocytes
from human embryonic stem cells by alternating retinoid signals. Cell Res. 21,
579–587.
Zhao, R., Watt, A.J., Battle, M.A., Li, J., Bondow, B.J., Duncan, S.A., 2008. Loss of both
GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia
in mice. Dev. Biol. 317, 614–619.
Zhou, W., Lin, L., Majumdar, A., Li, X., Zhang, X., Liu, W., Etheridge, L., Shi, Y., Martin,
J., Van de Ven, W., et al., 2007. Modulation of morphogenesis by noncanonical
Wnt signaling requires ATF/CREB family–mediated transcriptional activation of
TGFβ2. Nat. Genet. 39, 1225–1234.
Zhu, W.-Z., Xie, Y., Moyes, K.W., Gold, J.D., Askari, B., Laﬂamme, M.A., 2010.
Neuregulin/ErbB signaling regulates cardiac subtype speciﬁcation in differen-
tiating human embryonic stem cells. Circ. Res. 107, 776–786.
M.J. Birket, C.L. Mummery / Developmental Biology 400 (2015) 169–179 179
